Tufts CSDD Outlook

Tufts CSDD’s Outlook highlights near-term pharmaceutical and biopharmaceutical development trends. Data and analyses contained in Tufts CSDD’s Outlook are based on proprietary research conducted by the Tufts CSDD staff, and include insights into current industry, regulatory, and policy trends.

Here are the highlights of Tufts CSDD's Outlook 2016

  • Continued scientific achievements that increase understanding of the pathophysiology of oncological diseases will result in approvals of new cancer therapies, which will outpace new drug approvals in other therapeutic areas, as they have over the last 15 years.
  • Sponsors and CROs will make greater use of electronic medical information and drug development management metrics to perform more robust, predictive analytics to drive operating efficiency, improve feasibility, inform portfolio strategy, and support more effective patient recruitment.
  • Major regulatory agencies will emphasize harmonization of global activities to coordinate and facilitate pediatric studies, prompted by recent changes in policy that will increase the demand for pediatric patients to participate in clinical trials.
  • U.S. payers and providers will quantify clinical benefits of new cancer and orphan products to align price with value by measuring safety, effectiveness, convenience of use, and other attributes in relation to cost.

​Tufts CSDD's Outlook 2016 is now complimentary as of Monday, May 16, 2016, just send an email to .(JavaScript must be enabled to view this email address) to request your copy.


Press Releases